Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Molecular imaging to guide therapy: outline
- Anatomic vs. functional imaging
- Functional imaging modalities
- Positron emission tomography (PET)
- PET/CT
- Why radiotracer imaging?
- Existing cancer imaging paradigm
- FDG PET detects mammary nodal metastases
- A new paradigm for cancer imaging
- Imaging and targeted therapy
- Emerging cancer imaging paradigm
- Localize and characterize disease sites
- Image acquisition and quantitative analysis
- Choosing the right patients
- ER and breast cancer endocrine therapy
- FES: PET estrogen receptor (ER) imaging
- Validation: ER+ vs. ER- tumors
- PET provides estimate of ER expression
- FES predicts response to hormonal therapy (1)
- FES predicts response to hormonal therapy (2)
- Imaging hypoxia
- FMISO PET predicts outcome for GBM patients
- Hypoxia as a target for radiotherapy planning
- Imaging to direct hypoxia-specific treatment
- Choosing the right drug
- Resistance due to altered drug transport
- Imaging P-gp activity in vivo in humans
- FES PET measures pharmacodynamics
- Getting the right result
- Events in response to successful cancer therapy
- Thymidine incorporation pathways
- PET imaging pre- and post one cycle of Rx
- Thymidine analogs for cell proliferation imaging
- Early response measured by FLT PET
- FLT brain tumor imaging to measure response
- Bone metastasis response monitoring (1)
- Bone metastasis response monitoring (2)
- Change in FDG SUV correlates with response
- FDG uptake predicts outcome of breast cancer
- FDG PET/CT to monitor breast cancer response
- FDG PET vs. bone scan
- Predicting the outcome
- Neo-adjuvant therapy - PET assessment
- PET predicts survival after neo-adjuvant therapy
- Molecular imaging - measuring in vivo biology
- Changes in cancer metabolism and blood flow
- Results: multivariate DFS
- Flow-metabolism mismatch and poor response
- Match predicts path CR, mismatch: early relapse
- Metabolism-flow mismatch predicts poor outcome
- Altered metabolism and myocardial viability
- Glycolysis and angiogenesis
- Future directions
- ACRIN experimental imaging sciences committee
- Acknowledgements: UW PET cancer P01
- Breast cancer imaging research group
- Acknowledgements - collaborators
Topics Covered
- Anatomic vs. functional imaging
- Functional imaging modalities
- PET/CT
- Radiotracer imaging
- Existing cancer imaging paradigm
- A new paradigm for cancer imaging
- Imaging and targeted therapy
- Biomarker imaging
- ER expression and breast cancer endocrine therapy
- Hypoxia-specific treatment
- Biologic events in response to successful cancer therapy
- Thymidine incorporation pathways
- Bone metastasis response monitoring
- FDG PET vs. bone scan
- Neo-adjuvant therapy of breast cancer
- Molecular imaging is a tool for measuring in vivo biology
- Changes in breast cancer metabolism and blood flow predict pathologic response
- Clinical trial of novel molecular imaging probes for cancer
- ACRIN experimental imaging sciences committee
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mankoff, D. (2020, May 1). Clinical applications of molecular imaging: imaging to guide cancer therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/EFRS8783.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. David Mankoff has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Clinical applications of molecular imaging: imaging to guide cancer therapy
A selection of talks on Methods
Transcript
Please wait while the transcript is being prepared...
0:00
Good afternoon, this is David Mankoff,
and I'll be talking to you today about
clinical applications
of molecular imaging.
And in specific, we'll look at
imaging to guide cancer therapy,
0:13
today we'll start by looking
at some of the questions that
arise in trying to treat cancer patients
that imaging can be helpful for.
And we evaluate some of the methods
that we can use to address them, and
then we'll go on to show some examples
of recent work using cancer imaging and
then specific molecular imaging
to guide cancer therapy.
Number one by choosing the right patients,
number two by choosing the right drug
that we know will get to the target, and
number three, getting the right result,
and number four,
using imaging to try to predict outcome.
0:49
To start, we need to distinguish
anatomic versus functional imaging,
anatomic imaging is what most of us
are used to in clinical medicine and
in radiology, and are exemplified
by things like CT and mammography.
And here we rely on the tumor size,
shape and
density to be able to identify it, we
also look for changes in that same size,
shape and density to be able to
infer response to treatment.
And that's really been the gold
standard for many, many years and
is really what much of the current
practices is based upon.
Now, functional molecular imaging
are a bit different in that they rely on
in vivo tumor biology looking at processes
such as perfusion metabolism, and
more recently at the molecular features of
the tumors, to be able to generate images
and to be able to identify properties of
tumors in particular for cancer imaging.
Examples of this include MRI and PET, and
I'll be focusing mostly
on PET in this talk.
And one of the reasons that this kind of
approach would work better, we think, for
evaluating changes in response to therapy,
is that we would expect to
see these functional molecular changes
significantly precede changes in size,
shape and
density over the course of treatment.
In addition, these type of features might
be particularly helpful for trying to
choose the right kind of patients and help
choose the right drugs for those patients.
So if we think about what are the
different functional molecular imaging
Hide